These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 19855158)

  • 1. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation.
    Araujo JC; Poblenz A; Corn P; Parikh NU; Starbuck MW; Thompson JT; Lee F; Logothetis CJ; Darnay BG
    Cancer Biol Ther; 2009 Nov; 8(22):2153-9. PubMed ID: 19855158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts.
    Id Boufker H; Lagneaux L; Najar M; Piccart M; Ghanem G; Body JJ; Journé F
    BMC Cancer; 2010 Jun; 10():298. PubMed ID: 20565769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects.
    Garcia-Gomez A; Ocio EM; Crusoe E; Santamaria C; Hernández-Campo P; Blanco JF; Sanchez-Guijo FM; Hernández-Iglesias T; Briñón JG; Fisac-Herrero RM; Lee FY; Pandiella A; San Miguel JF; Garayoa M
    PLoS One; 2012; 7(4):e34914. PubMed ID: 22539950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
    Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo.
    Vandyke K; Dewar AL; Diamond P; Fitter S; Schultz CG; Sims NA; Zannettino AC
    J Bone Miner Res; 2010 Aug; 25(8):1759-70. PubMed ID: 20225261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
    Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE
    Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
    Yang JC; Bai L; Yap S; Gao AC; Kung HJ; Evans CP
    Mol Cancer Ther; 2010 Jun; 9(6):1629-37. PubMed ID: 20484016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.
    Koreckij T; Nguyen H; Brown LG; Yu EY; Vessella RL; Corey E
    Br J Cancer; 2009 Jul; 101(2):263-8. PubMed ID: 19603032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
    Shor AC; Keschman EA; Lee FY; Muro-Cacho C; Letson GD; Trent JC; Pledger WJ; Jove R
    Cancer Res; 2007 Mar; 67(6):2800-8. PubMed ID: 17363602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.
    Lee YC; Huang CF; Murshed M; Chu K; Araujo JC; Ye X; deCrombrugghe B; Yu-Lee LY; Gallick GE; Lin SH
    Oncogene; 2010 Jun; 29(22):3196-207. PubMed ID: 20228840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
    Ohno H; Kubo K; Murooka H; Kobayashi Y; Nishitoba T; Shibuya M; Yoneda T; Isoe T
    Mol Cancer Ther; 2006 Nov; 5(11):2634-43. PubMed ID: 17121910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.
    Karim SA; Creedon H; Patel H; Carragher NO; Morton JP; Muller WJ; Evans TR; Gusterson B; Sansom OJ; Brunton VG
    J Pathol; 2013 Aug; 230(4):430-40. PubMed ID: 23616343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.
    Nam S; Kim D; Cheng JQ; Zhang S; Lee JH; Buettner R; Mirosevich J; Lee FY; Jove R
    Cancer Res; 2005 Oct; 65(20):9185-9. PubMed ID: 16230377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.
    Araujo J; Logothetis C
    Cancer Treat Rev; 2010 Oct; 36(6):492-500. PubMed ID: 20226597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain.
    Appel CK; Gallego-Pedersen S; Andersen L; Blancheflor Kristensen S; Ding M; Falk S; Sayilekshmy M; Gabel-Jensen C; Heegaard AM
    Sci Rep; 2017 Jul; 7(1):4792. PubMed ID: 28684771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quercetin suppresses bone resorption by inhibiting the differentiation and activation of osteoclasts.
    Woo JT; Nakagawa H; Notoya M; Yonezawa T; Udagawa N; Lee IS; Ohnishi M; Hagiwara H; Nagai K
    Biol Pharm Bull; 2004 Apr; 27(4):504-9. PubMed ID: 15056855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cysteine proteinase inhibitors regulate human and mouse osteoclastogenesis by interfering with RANK signaling.
    Strålberg F; Henning P; Gjertsson I; Kindlund B; Souza PP; Persson E; Abrahamson M; Kasprzykowski F; Grubb A; Lerner UH
    FASEB J; 2013 Jul; 27(7):2687-701. PubMed ID: 23572233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
    Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
    J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1.
    Sankar U; Patel K; Rosol TJ; Ostrowski MC
    J Bone Miner Res; 2004 Aug; 19(8):1339-48. PubMed ID: 15231022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of Osteoclast Differentiation at Multiple Stages by Protein Kinase D Family Kinases.
    Leightner AC; Mello Guimaraes Meyers C; Evans MD; Mansky KC; Gopalakrishnan R; Jensen ED
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.